Table 1.
Role of the 5-HT2A receptors in temporal lobe epilepsy.
| Model | Effect | Reference | ||
|---|---|---|---|---|
| Antiepileptic role of the 5-HT2A receptors in temporal lobe epilepsy | ||||
| Antagonists | MDL 11,939 (5-HT2A) | MEST test in Lmx1bf/f/p mice | Blocked DOI-TCB-2 effect in preventing seizure-induced respiratory arrest and death | Buchanan et al. (2014) |
| Ketanserin (5-HT2A) | MEST test in mice | Decreases the threshold for seizures | Przegaliński et al. (1994) | |
| Ritanserin (5-HT2A/2B/2C) | MEST test in mice | Decreases the threshold for seizures | ||
| MDL 100907 (5-HT2A) | Electroshock-induced hippocampal partial seizures in rats | Increases primary AD duration | Watanabe et al. (2000) | |
| Agonists | DOI (5-HT2A/2C) TCB-2 (5-HT2A) | MEST test in Lmx1bf/f/p mice | Prevented seizure-induced respiratory arrest and death | Buchanan et al. (2014) |
| mCPP (5-HT2A/2B/2C) | MDA in rats | Stop MDA elongation (not blocked by SB242084) | Orban et al. (2014) | |
| Lorcaserin (5-HT2B/2C) | MDA in rats | Stop MDA elongation (not blocked by SB242084) | ||
| DOI (5-HT2A/2C) | Hippocampal kindled seizures in rats | Reduces AD duration | Wada et al. (1992) | |
| Pro-epileptic role of the 5-HT2A receptors | ||||
| Antagonists | Antisense oligonucleotide designed to inhibit 5-HT2A expression | Tryptamine-induced serotonergic syndrome-associated convulsions | Inhibited tryptamine-induced bilateral convulsions and body tremors | Van Oekelen et al. (2003) |
| MDL100907 (5-HT2A) | Feline hippocampal kindled seizures | No effect on seizure thresholds, secondary AD duration, or latency of secondary AD | Watanabe et al. (2000) | |
| Ritanserin (5-HT2A/2B/2C) | Kainic acid-induced seizures in rats | Has no effect | Velisek et al. (1994) | |
| Ketanserin (5-HT2A) | Cocaine-induced convulsions in mice | Dose-dependently inhibits seizures | Ritz and George (1997) | |
| Hippocampal kindled seizures in cats | Increases latency to generalized convulsions | Wada et al. (1992) | ||
| Amygdala kindling in rats | Delays the development of kindling | Wada et al. (1997) | ||
| Picrotoxin-induced seizures in stressed and unstressed mice | Has no effect on seizure thresholds | Pericic et al. (2005) | ||
| Ethanol-withdrawal seizures in mice | Has no effect on seizure severity | Grant et al. (1994) | ||
| Cinanserin (5-HT2A/2C) | Cocaine-induced convulsions in mice | Dose-dependently inhibits seizures | Ritz and George (1997) | |
| Pirenperone (5-HT2A/2C) | Cocaine-induced convulsions in mice | Dose-dependently inhibits seizures | ||
| Dotarizine (5-HT2A/2C) | Electroshock-induced seizures in rats | Increases the threshold for seizures | Lazarova et al. (1995) | |
| PTZ-induced seizures in rats | Has no effect on seizure thresholds | |||
| Agonists | DOI (5-HT2A/2C) | Hippocampal kindled seizures in cats | Decreases latency to generalized convulsions | Wada et al. (1992) |
| Amygdala kindling in rats | Facilitates kindling and reduces the number of stimulations needed to elicit generalized convulsions | Wada et al. (1997) | ||
| Picrotoxin-induced seizures in stressed and unstressed mice | Has no effect on seizure thresholds | Pericic et al. (2005) |
MEST, maximal electroshock threshold; PTZ, pentylenetetrazole; SE, status epilepticus.